Everything below concerns ACTH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
The ELISA template, commonly used for performing immunoassays and other enzyme-based biochemical assays, has been adapted for use with the DMF platform for the detection of analytes such as IgE and IgG. In one example, a series of bioassays were conducted to establish the quantification capabilities of DMF devices, including an ELISA-based immunoassay for the detection of IgE. Superparamagnetic nanoparticles were immobilized with anti-IgE antibodies and fluorescently labeled aptamers to quantify IgE using an ELISA template. Similarly, for the detection of IgG, IgG can be immobilized onto a DMF chip, conjugated with horseradish-peroxidase (HRP)-labeled IgG, and then quantified through measurement of the color change associated with product formation of the reaction between HRP and tetramethylbenzidine. To further expand the capabilities and applications of DMF immunoassays beyond colorimetric detection (i.e., ELISA, magnetic bead-based assays), electrochemical detection tools (e.g., microelectrodes) have been incorporated into DMF chips for the detection of analytes such as TSH and rubella virus. For example, Rackus et al. integrated microelectrodes onto a DMF chip surface and substituted a previously reported chemiluminescent IgG immunoassay with an electroactive species, enabling detection of rubella virus. They coated magnetic beads with rubella virus, anti-rubella IgG, and anti-human IgG coupled with alkaline phosphatase, which in turn catalyzed an electron transfer reaction that was detected by the on-chip microelectrodes.
== Chemistry == In terms of chemical structure, BRD-6929 is an ortho-aminoanilide or benzamide and is a close analogue of tacedinaline (CI-994), differing from it only in the addition of a thiophene ring on one of the phenyl rings.
10 October — Local authorities activate emergency operations centres in the Grey and Buller Districts in response to heavy rainfall, flooding and landslides. MetService issues heavy rain and wind warnings for that region. 11 October: The 2025 local elections, including local referendums on Māori wards and constituencies, conclude. 24 district and regional councils vote to remove their Māori wards and constituencies while 18 others vote to retain them. 14 October: Minister for Rail Winston Peters confirms that the New Zealand Government has contracted the Chinese state-owned shipyard COMEC to build two new rail-enabled Interislander ferries, which are expected to be delivered in 2029. The New Zealand Parliament passes legislation allowing radio and television stations to broadcast advertisements on Christmas Day, Good Friday, Easter Sunday and Anzac Day. Heavy rain causes flooding in the Waitomo and Ruapehu Districts in the central North Island, affecting several farms, roads, and some houses. Mayor of Waitomo John Robertson estimates the flood damage to be in the regions. 17 October: Highways reopen in the flood-stricken Waitomo and Ruapehu Districts. The New Zealand Professional Firefighters Union (NZPFU) held a one hour strike following the breakdown of pay negotiations broke down with Fire and Emergency New Zealand. The New Zealand Government reinstates several United Nations sanctions against Iran including asset freezes, travel bans and trade restrictions after Iran withdraws from the JCPOA agreements in September 2025.
=== Method Development === Method development of chiral chromatography is still done by screening of columns from the various classes of chiral columns. While chiral separation mechanisms are understandable in certain scenarios, and the retention characteristics of analytes within the chromatographic columns can occasionally be elucidated, the precise combination of chiral stationary phases (CSPs) and mobile-phase compositions that required to effectively resolve a specific enantiomeric pair often remains elusive. The chemistry of CSP ligands significantly influences the creation of in-situ diastereomeric complexes upon the stationary phase surface. However, other method's conditions, such as mobile-phase solvents, their composition, mobile phase additives and column temperature can play equally critical roles. The final resolution of the enantiomers is the outcome of combination of intermolecular forces, and even a subtle change in them can determine the success or failure of separation. This complexity prevents from establishing routine method-development protocols that are universally applicable to a diverse range of enantiomers. In fact, sometimes the outcome of previous unsuccessful experiments do not provide any clue for the subsequent steps.
Sources: en.wikipedia.org
=== Opioid liability === Systemic agmatine can potentiate opioid analgesia, and prevent tolerance to chronic morphine in laboratory rodents. Since then, cumulative evidence amply shows that agmatine inhibits opioid dependence and relapse in several animal species.
== See also == Difluoromethyldopa D-DOPA (dextrodopa) L-DOPA (levodopa; trade names Sinemet, Pharmacopa, Atamet, Stalevo, Madopar, Prolopa, etc.) L-DOPS (droxidopa) Dopamine (Intropan, Inovan, Revivan, Rivimine, Dopastat, Dynatra, etc.) Norepinephrine (noradrenaline; Levophed, etc.) Epinephrine (adrenaline; Adrenalin, EpiPed, Twinject, etc.) MK-872 HCl salt: [55943-64-1] α-Methyltyrosine α-Methyl-5-hydroxytryptophan
== Prevalence == The prevalence of Osborne's ligament has been inconsistently reported, ranging from 8% through 77% to 100% in cadavers across different studies. The inconsistency can be attributed to the unestablished definition of the tissue.
=== Use of Oriented Peptide Libraries to determine phosphopeptide binding specificity and protein kinase substrate specificity === In 1994, the Cantley lab published a novel strategy to determine the sequence specificity of phosphopeptide binding domains (initially SH2 domains). Subsequently, the oriented peptide library approach was extended to identify the substrate specificity of protein kinases toward synthetic peptides. This approach was then extended to characterize the specificity of Ser/Thr kinases and phospho-Ser/Thr binding domains. This approach was used to characterize the substrate specificity of a large number of protein kinases. The kinase specificity matrices generated from these experiments served as the basis for creating the website Scansite, allowing the de novo identification of candidate phosphorylation sites in an arbitrary protein. In later research, the oriented peptide library approach has also been used to characterize protease cleavage specificity. Modification of the original oriented peptide approach has allowed for large scale, kinome-wide determination of protein kinase specificity.
The hypothalamus is highly interconnected with other parts of the central nervous system, in particular the brainstem and its reticular formation. As part of the limbic system, it has connections to other limbic structures including the amygdala and septum, and is also connected with areas of the autonomous nervous system. The hypothalamus receives many inputs from the brainstem, the most notable from the nucleus of the solitary tract, the locus coeruleus, and the ventrolateral medulla. Most nerve fibres within the hypothalamus run in two ways (bidirectional).
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.